Clinical Significance of Circulating DNA Microsatellite Markers in Plasma of Melanoma Patients
Clinical Significance of Circulating DNA Microsatellite Markers in Plasma of Melanoma Patients
复制标题
黑色素瘤患者血浆中循环 DNA 微卫星标记的临床意义
DOI：
--
复制
发表时间：
2000
影响因子：
5.2
通讯作者：
D. Hoon
中科院分区：
文献类型：
--
作者：
T. Nakayama;B. Taback;DUC‐HANH Nguyen;D. Chi;D. Morton;Y. Fujiwara;D. Hoon
黑色素瘤是困扰人类的最具侵略性的肿瘤之一。虽然它仅占美国诊断出的所有癌症的1-3%，但其发病率的上升速度比任何其他恶性肿瘤都要快。1很大比例的患者将出现美国癌症联合委员会（AJCC）II期或晚期疾病，并且在一些系列中报告其区域或远处复发的风险高达80%。一旦诊断出远处转移，预计5年生存率低于5%。2黑色素瘤的独特之处在于其侵袭性行为，转移的多样性不可预测。远处转移最常发生在脑、肺和肝。据报道，黑色素瘤也是转移到胃肠道的最常见的腹部外肿瘤。单药化疗的良好反应有限，联合治疗如生物化疗方案仍在评估中。免疫治疗，如疫苗，似乎是有效的淋巴结阳性患者;然而，那些与远处转移往往是难治性的大多数干预。2，3由于这些原因，它是当务之急，以确定患者在疾病切除后疾病复发的风险较高，更重要的是，以确定那些个体与系统性进展性疾病。
Melanoma is one of the most aggressive tumors afflicting humankind. Although it accounts for only 1–3% of all cancers diagnosed in the United States, the incidence is rising more rapidly than that of any other malignancy.1 A large percentage of patients will present with American Joint Committee on Cancer (AJCC) stage II or advanced disease, and their risk for regional or distant recurrence has been reported as high as 80% in some series. Once diagnosed with distant metastasis, the expected 5-year survival is less than 5%.2 Unique to melanoma is its aggressive behavior with an unpredictable diversity for metastasis. Distant metastasis occurs most frequently to the brain, lungs, and liver. Melanoma is also reported to be the most common extra-abdominal tumor to metastasize to the gastrointestinal tract. Favorable response to single-agent chemotherapy has been limited, and the addition of combination therapies such as biochemotherapy regimens is still being evaluated. Immunotherapy, such as vaccine, appears to be effective in node-positive patients; however, those with distant metastasis are often refractory to most interventions.2,3 For these reasons, it is imperative to identify patients at higher risk for disease recurrence after disease removal and, more so, to determine those individuals with systemic progressive disease.
登录
查看更多内容
影响因子：
11.2
作者：
T. Sarantou;D. Chi;D. Garrison;A. Conrad;P. Schmid;D. Morton;D. Hoon
通讯作者：
T. Sarantou;D. Chi;D. Garrison;A. Conrad;P. Schmid;D. Morton;D. Hoon
黑色素瘤中细胞周期蛋白依赖性激酶 4 抑制剂基因 CDK4I 的体细胞和种系突变罕见。
影响因子：
11.2
作者：
Ohta,M;Nagai,H;Shimizu,M;Rasio,D;Berd,D;Mastrangelo,M;Singh,AD;Shields,JA;Shields,CL;Croce,CM
通讯作者：
Croce,CM
早期黑色素瘤患者通过前哨淋巴结切除术和逆转录聚合酶链反应检测到的隐匿性转移的预后意义。
DOI：
10.1200/jco.1999.17.10.3238
发表时间：
1999
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Bostick,PJ;Morton,DL;Turner,RR;Huynh,KT;Wang,HJ;Elashoff,R;Essner,R;Hoon,DS
通讯作者：
Hoon,DS
影响因子：
--
作者：
V. Talwalkar;M. S. Scheiner;L. Hedges;M. Butler;Herbert S. Schwartz
通讯作者：
V. Talwalkar;M. S. Scheiner;L. Hedges;M. Butler;Herbert S. Schwartz
DOI：
10.1073/pnas.89.21.10557
发表时间：
1992-11-01
影响因子：
11.1
作者：
FOUNTAIN, JW;KARAYIORGOU, M;DRACOPOLI, NC
通讯作者：
DRACOPOLI, NC